A phase 3 study among Chinese patients for an eye drug co-developed by Shanghai Henlius Biotech (HKG:2696) and Essex Bio-Technology (HKG:1061) reached the primary study endpoints, according to separate Wednesday filings with the Hong Kong bourse.
The two companies co-developed the HLX04-O injection for wet age-related macular degeneration patients.
The drug contains thee recombinant anti-vascular endothelial growth factor humanised monoclonal antibody, according to Essex's filing.
Wet age-related macular degeneration patients experience abnormal growth of blood vessels under the retina which could lead to rapid vision loss.
Shares in Essex surged nearly 11%, while that of Henlius fell 4% during late morning trading Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。